bloodjourГематология и трансфузиологияRussian journal of hematology and transfusiology0234-57302411-3042ООО Издательский дом «Практика»10.35754/0234-5730-2022-67-2-261-266bloodjour-366Research ArticleОБЗОРЫREVIEWSРоль D-димера в прогнозировании риска инсульта у больных с фибрилляцией предсердийThe role of D-dimer in stroke risk stratification in patients with atrial fibrillationhttps://orcid.org/0000-0002-3996-4689РубаненкоА. О.RubanenkoA. O.

Рубаненко Анатолий Олегович, кандидат медицинских наук, доцент кафедры пропедевтической терапии

443099, Самара

Anatolii O. Rubanenko — Cand. Sci. (Med.), Associate Professor at the Department of Propedeutic Therapy

443099, Samara

anatolii.rubanenko@gmail.comhttps://orcid.org/0000-0001-9351-6177РубаненкоО. А.RubanenkoO. A.

Рубаненко Олеся Анатольевна, кандидат медицинских наук, доцент кафедры госпитальной терапии с курсами поликлинической терапии и трансфузиологии

443099, Самара

Olesya A. Rubanenko — Cand. Sci. (Med.), Associate Professor of the Department of Hospital Therapy with Courses of Polyclinic Therapy and Transfusiology

443099, Samara

olesya.rubanenko@gmail.comhttps://orcid.org/0000-0001-8891-6088ДьячковВ. А.DyachkovV. A.

Дьячков Владислав Александрович, кандидат медицинских наук, доцент кафедры пропедевтической терапии

443099, Самара

Vladislav A. Dyachkov, Cand. Sci. (Med.), Associate Professor of the Department of Propaedeutic Therapy

443099, Samara

gelios-13@mail.ruhttps://orcid.org/0000-0003-0387-8356ЩукинЮ. В.ShchukinYu. V.

Щукин Юрий Владимирович, доктор медицинских наук, профессор, заведующий кафедрой пропедевтической терапии

443099, Самара

Yuri V. Shchukin, Doct. Sci. (Med.), Professor, Head of Propaedeutic Therapy Department

443099, Samara

samgmu_pt@mail.ruФедеральное государственное бюджетное образовательное учреждение высшего образования «Самарский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияSamara State Medical UniversityRussian Federation202207072022672261266Copyright © Рубаненко А.О., Рубаненко О.А., Дьячков В.А., Щукин Ю.В., 20222022Рубаненко А.О., Рубаненко О.А., Дьячков В.А., Щукин Ю.В.Rubanenko A.O., Rubanenko O.A., Dyachkov V.A., Shchukin Y.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.htjournal.ru/jour/article/view/366Введение

Введение. D-димер отражает активность процессов внутрисосудистого свертывания крови и системы фибринолиза. Имеются данные, подтверждающие связь между повышением в плазме концентрации D-димера и развитием инсульта у больных с фибрилляцией предсердий (ФП). Однако D-димер не включен в шкалы оценки риска развития этого осложнения у больных с ФП.

Цель — анализ данных о значении D-димера в прогнозировании риска развития инсульта у больных с ФП.

Основные сведения

Основные сведения. D-димер, несмотря на некоторые ограничения, может использоваться в качестве показателя, ассоциирующегося с развитием инсульта у больных с ФП. Определение концентрации D-димера в плазме может быть полезным для решения вопроса о проведении антикоагулянтной терапии у больных с ФП, имеющих низкий риск по шкале CHA2DS2-VASc, или набирающих один балл, не связанный с полом.

Introduction

Introduction. D-dimer is an important indicator, which reflects the activation of intravascular blood coagulation and fibrinolytic system. There are some data confirming that D-dimer is associated with stroke development in patients with atrial fibrillation. However, D-dimer is not included in modern stoke risk stratification scales in patients with atrial fibrillation.

Aim — to analyze the data devoted to the role of D-dimer in stroke risk stratification in patients with atrial fibrillation.

General findings

General findings. D-dimer, despite several limitations, could be used in clinical practice as an indicator that is associated with stroke development in patients with atrial fibrillation. D-dimer level estimation could help to decide whether to use anticoagulant treatment in patients with low risk of stroke development or in those patients with a single non-sex CHA2DS2-VASc score risk factor.

D-димерфибрилляция предсердийинсультпрогнозированиеD-dimeratrial fibrillationstrokeprognosisReferencesСкворцова В.И., Шетова И.М., Какорина Е.П. и др. Организация помощи пациентам с инсультом в России. Итоги 10 лет реализации Комплекса мероприятий по совершенствованию медицинской помощи пациентам с острыми нарушениями мозгового кровообращения. Анналы клинической и экспериментальной неврологии. 2018; 12(3): 5–12. DOI: 10.25692/ACEN.2018.3.1.Skvortsova V.I., Shetova I.M., Kakorina E.P., et al. Healthcare system for patients with stroke in Russia. Results of 10-years implementation of the measures aimed at improvement of medical care for patients with acute cerebrovascular events. Annaly klinicheskoy I experimentalnoy nevrologii. 2018; 12(3): 5–12. DOI: 10.25692/ACEN.2018.3.1. (In Russian).Самсонова Н.А., Карпова М.И., Москвичева М.Г. Клиническая и экспертная характеристика больных с инсультом, впервые признанных инвалидами. Здоровье и образование в XXI веке. 2016; 18(10): 35–41.Samsonova N.A., Karpova M.I., Moskvicheva M.G. Clinical and expert characteristics of patients with stroke, for the first time recognized as disabled. Zdorov'e i obrazovanie v XXI veke. 2016; 18(10): 35–41. (In Russian).Дамулин И.В, Андреев Д.А., Салпагарова З.К. Кардиоэмболический инсульт. Неврология, нейропсихиатрия, психосоматика. 2015; (1): 80–6. DOI: 10.14412/2074-2711-2015-1-80-86.Damulin I.V, Andreev D.A, Salpagarova Z.K. Cardioembolic stroke. Nevrologiya, Neuropsychiatriya, Psychosomatika. 2015; (1): 80–6. DOI: 10.14412/2074-2711-2015-1-80-86. (In Russian).Hindricks G., Potpara T., Dagres N., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021; 42(5): 373–498. DOI: 10.1093/eurheartj/ehaa612.Hindricks G., Potpara T., Dagres N., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021; 42(5): 373–498. DOI: 10.1093/eurheartj/ehaa612.Kamel H., Healey J.S. Cardioembolic stroke. Circ Res. 2017; 120(3): 514–26. DOI: 10.1161/CIRCRESAHA.116.308407.Kamel H., Healey J.S. Cardioembolic stroke. Circ Res. 2017; 120(3): 514–26. DOI: 10.1161/CIRCRESAHA.116.308407.Kirchhof P., Breithardt G., Camm AJ., et al. Improving outcomes in patients with atrial fibrillation: Rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial. Am Heart J. 2013; 166(3): 442–8. DOI: 10.1016/j.ahj.2013.05.015.Kirchhof P., Breithardt G., Camm AJ., et al. Improving outcomes in patients with atrial fibrillation: Rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial. Am Heart J. 2013; 166(3): 442–8. DOI: 10.1016/j.ahj.2013.05.015.Zhu W., Fu L., Ding Y., et al. Meta-analysis of ATRIA versus CHA 2 DS 2 -VASc for predicting stroke and thromboembolism in patients with atrial fibrillation. Int J Cardiol. 2017; 227: 436–42. DOI: 10.1016/j.ijcard.2016.11.015.Zhu W., Fu L., Ding Y., et al. Meta-analysis of ATRIA versus CHA 2 DS 2 -VASc for predicting stroke and thromboembolism in patients with atrial fibrillation. Int J Cardiol. 2017; 227: 436–42. DOI: 10.1016/j.ijcard.2016.11.015.Singer D.E., Chang Y., Borowsky L.H., et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: The ATRIA study stroke risk score. J Am Heart Assoc. 2013; 2(3): e000250. DOI: 10.1161/JAHA.113.000250.Singer D.E., Chang Y., Borowsky L.H., et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: The ATRIA study stroke risk score. J Am Heart Assoc. 2013; 2(3): e000250. DOI: 10.1161/JAHA.113.000250.Graves K.G., May H.T., Knowlton K.U., et al. Improving CHA 2 DS 2 -VASc stratification of non-fatal stroke and mortality risk using the Intermountain Mortality Risk Score among patients with atrial fibrillation. Open Heart. 2018; 5(2): e000907. DOI: 10.1136/openhrt-2018-000907.Graves K.G., May H.T., Knowlton K.U., et al. Improving CHA 2 DS 2 -VASc stratification of non-fatal stroke and mortality risk using the Intermountain Mortality Risk Score among patients with atrial fibrillation. Open Heart. 2018; 5(2): e000907. DOI: 10.1136/openhrt-2018-000907.Hijazi Z., Lindback J., Alexander J.H., et al. ARISTOTLE and STABILITY Investigators. The ABC (age, biomarkers, clinical history) stroke risk score: A biomarkerbased risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016; 37(20): 1582–90. DOI: 10.1093/eurheartj/ehw054.Hijazi Z., Lindback J., Alexander J.H., et al. ARISTOTLE and STABILITY Investigators. The ABC (age, biomarkers, clinical history) stroke risk score: A biomarkerbased risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016; 37(20): 1582–90. DOI: 10.1093/eurheartj/ehw054.Watson T., Shantsila E., Lip G.Y. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet. 2009; 373(9658): 155–66. DOI: 10.1016/S0140-6736(09)60040-4.Watson T., Shantsila E., Lip G.Y. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet. 2009; 373(9658): 155–66. DOI: 10.1016/S0140-6736(09)60040-4.Danese E., Montagnana M., Cervellin G., Lippi G. Hypercoagulability, D-dimer and atrial fibrillation: An overview of biological and clinical evidence. Ann Med. 2014; 46(6): 364–71. DOI: 10.3109/07853890.2014.912835.Danese E., Montagnana M., Cervellin G., Lippi G. Hypercoagulability, D-dimer and atrial fibrillation: An overview of biological and clinical evidence. Ann Med. 2014; 46(6): 364–71. DOI: 10.3109/07853890.2014.912835.Wu N., Tong S., Xiang Y., et al. Association of hemostatic markers with atrial fibrillation: A meta-analysis and meta-regression. PLoS One. 2015; 10(4): e0124716. DOI: 10.1371/journal.pone.0124716Wu N., Tong S., Xiang Y., et al. Association of hemostatic markers with atrial fibrillation: A meta-analysis and meta-regression. PLoS One. 2015; 10(4): e0124716. DOI: 10.1371/journal.pone.0124716Johnson E.D., Schell J.C., Rodgers G.M. The D-dimer assay. Am J Hematol. 2019; 94(7): 833–9. DOI: 10.1002/ajh.25482.Johnson E.D., Schell J.C., Rodgers G.M. The D-dimer assay. Am J Hematol. 2019; 94(7): 833–9. DOI: 10.1002/ajh.25482.Olson J.D. D-dimer: An overview of hemostasis and fibrinolysis, assays, and clinical applications. Adv Clin Chem. 2015; 69: 1–46. DOI: 10.1016/bs.acc.2014.12.001.Olson J.D. D-dimer: An overview of hemostasis and fibrinolysis, assays, and clinical applications. Adv Clin Chem. 2015; 69: 1–46. DOI: 10.1016/bs.acc.2014.12.001.Weitz J.I., Fredenburgh J.C., Eikelboom J.W. A test in context: D-dimer. J Am Coll Cardiol. 2017; 70(19): 2411–20. DOI: 10.1016/j.jacc.2017.09.024.Weitz J.I., Fredenburgh J.C., Eikelboom J.W. A test in context: D-dimer. J Am Coll Cardiol. 2017; 70(19): 2411–20. DOI: 10.1016/j.jacc.2017.09.024.Christersson C., Wallentin L., Andersson U., et al. D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation -observations from the ARISTOTLE trial. J Thromb Haemost. 2014; 12(9): 1401–12. DOI: 10.1111/jth.12638.Christersson C., Wallentin L., Andersson U., et al. D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation -observations from the ARISTOTLE trial. J Thromb Haemost. 2014; 12(9): 1401–12. DOI: 10.1111/jth.12638.Siegbahn A., Oldgren J., Andersson U., et al. D-dimer and factor VIIa in atrial fibrillation – prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy. Thromb Haemost. 2016; 115(5): 921–30. DOI: 10.1160/TH15-07-0529.Siegbahn A., Oldgren J., Andersson U., et al. D-dimer and factor VIIa in atrial fibrillation – prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy. Thromb Haemost. 2016; 115(5): 921–30. DOI: 10.1160/TH15-07-0529.Choi K.H., Seo W.K., Park M.S., et al. Baseline D-dimer levels as a risk assessment biomarker for recurrent stroke in patients with combined atrial fibrillation and atherosclerosis. J Clin Med. 2019; 8(9): 1457. DOI: 10.3390/jcm8091457.Choi K.H., Seo W.K., Park M.S., et al. Baseline D-dimer levels as a risk assessment biomarker for recurrent stroke in patients with combined atrial fibrillation and atherosclerosis. J Clin Med. 2019; 8(9): 1457. DOI: 10.3390/jcm8091457.Paulin B.K., Cedric K.K., Tamomh A.G., et al. Assessment of cardiac biomarkers (troponin, B-type natriuretic peptide, and D-dimer) in patients with non-valvular atrial fibrillation and stroke. Int J Health Sci (Qassim). 2019; 13(6): 3–12.Paulin B.K., Cedric K.K., Tamomh A.G., et al. Assessment of cardiac biomarkers (troponin, B-type natriuretic peptide, and D-dimer) in patients with non-valvular atrial fibrillation and stroke. Int J Health Sci (Qassim). 2019; 13(6): 3–12.You L.R., Tang M. The association of high D-dimer level with high risk of ischemic stroke in nonvalvular atrial fibrillation patients: A retrospective study. Medicine. 2018; 97(43): e12622. DOI: 10.1097/MD.0000000000012622.You L.R., Tang M. The association of high D-dimer level with high risk of ischemic stroke in nonvalvular atrial fibrillation patients: A retrospective study. Medicine. 2018; 97(43): e12622. DOI: 10.1097/MD.0000000000012622.Matsumoto M., Sakaguchi M., Okazaki S., et al. Relationship between plasma (D)-dimer level and cerebral infarction volume in patients with nonvalvular atrial fibrillation. Cerebrovasc Dis. 2013; 35(1): 64–72. DOI: 10.1159/000345336.Matsumoto M., Sakaguchi M., Okazaki S., et al. Relationship between plasma (D)-dimer level and cerebral infarction volume in patients with nonvalvular atrial fibrillation. Cerebrovasc Dis. 2013; 35(1): 64–72. DOI: 10.1159/000345336.Hijazi Z., Oldgren J., Siegbahn A., Wallentin L. Application of biomarkers for risk stratification in patients with atrial fibrillation. Clin Chem. 2017; 63(1): 152–64. DOI: 10.1373/clinchem.2016.255182.Hijazi Z., Oldgren J., Siegbahn A., Wallentin L. Application of biomarkers for risk stratification in patients with atrial fibrillation. Clin Chem. 2017; 63(1): 152–64. DOI: 10.1373/clinchem.2016.255182.Hall A., Simpson R.F.G., Mitchell A.R.J. Biomarker assays for personalised stroke risk assessment in atrial fibrillation. Cardiovasc Hematol Disord Drug Targets. 2017; 17(1): 58–63. DOI: 10.2174/1871529X17666170104120746.Hall A., Simpson R.F.G., Mitchell A.R.J. Biomarker assays for personalised stroke risk assessment in atrial fibrillation. Cardiovasc Hematol Disord Drug Targets. 2017; 17(1): 58–63. DOI: 10.2174/1871529X17666170104120746.Savinolli J.A., Halperin J.L. Should patients with atrial fibrillation and 1 stroke risk factor (CHA 2 DS 2 -VASc score 1 in men, 2 in WOMEN) be anticoagulated? The CHA 2 DS 2 ‐VASc 1 conundrum: Decision making at the lower end of the risk spectrum. Circulation. 2016; 133(15): 1504–11. DOI: 10.1161/CIRCULATIONAHA.115.016715.Savinolli J.A., Halperin J.L. Should patients with atrial fibrillation and 1 stroke risk factor (CHA 2 DS 2 -VASc score 1 in men, 2 in WOMEN) be anticoagulated? The CHA 2  DS 2 ‐VASc 1 conundrum: Decision making at the lower end of the risk spectrum. Circulation. 2016; 133(15): 1504–11. DOI: 10.1161/CIRCULATIONAHA.115.016715.Linkins L.A., Takach Lapner S. Review of D-dimer testing: Good, bad, and ugly. Int J Lab Hematol. 2017; 39(Suppl 1): 98–103. DOI: 10.1111/ijlh.12665.Linkins L.A., Takach Lapner S. Review of D-dimer testing: Good, bad, and ugly. Int J Lab Hematol. 2017; 39(Suppl 1): 98–103. DOI: 10.1111/ijlh.12665.Rostami M., Mansouritorghabeh H. D-dimer level in COVID-19 infection: A systematic review. Expert Rev Hematol. 2020; 13(11): 1265–75. DOI: 10.1080/17474086.2020.1831383.Rostami M., Mansouritorghabeh H. D-dimer level in COVID-19 infection: A systematic review. Expert Rev Hematol. 2020; 13(11): 1265–75. DOI: 10.1080/17474086.2020.1831383.Garcia G.I., Canadas P.P., Uriarte J.M., et al. D-dimer during pregnancy: Establishing trimester-specific reference intervals. Scand J Clin Lab Invest. 2018; 78(6): 439–42. DOI: 10.1080/00365513.2018.1488177.Garcia G.I., Canadas P.P., Uriarte J.M., et al. D-dimer during pregnancy: Establishing trimester-specific reference intervals. Scand J Clin Lab Invest. 2018; 78(6): 439–42. DOI: 10.1080/00365513.2018.1488177.Haase C., Joergensen M., Ellervik C., et al. Age- and sex-dependent reference intervals for D-dimer: Evidence for a marked increase by age. Thromb Res. 2013; 132(6): 676–80. DOI: 10.1016/j.thromres.2013.09.033.Haase C., Joergensen M., Ellervik C., et al. Age- and sex-dependent reference intervals for D-dimer: Evidence for a marked increase by age. Thromb Res. 2013; 132(6): 676–80. DOI: 10.1016/j.thromres.2013.09.033.Righini M., Van Es J., Den Exter P.L., et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: The ADJUST-PE study. JAMA. 2014; 311(11): 1117–24. DOI: 10.1001/jama.2014.2135.Righini M., Van Es J., Den Exter P.L., et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: The ADJUST-PE study. JAMA. 2014; 311(11): 1117–24. DOI: 10.1001/jama.2014.2135.Shin S.Y., Han S.J., Kim J.S., et al. Identification of markers associated with development of stroke in “clinically low-risk” atrial fibrillation patients. J Am Heart Assoc. 2019; 8(21): e012697. DOI: 10.1161/JAHA.119.012697.Shin S.Y., Han S.J., Kim J.S., et al. Identification of markers associated with development of stroke in “clinically low-risk” atrial fibrillation patients. J Am Heart Assoc. 2019; 8(21): e012697. DOI: 10.1161/JAHA.119.012697.

The authors declare that there are no conflicts of interest present.